Clinical trials
Immunogenicity clinical trials
Below are recruiting immunogenicity clinical trials, each written for real people, not researchers. We’re tracking 146 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07557420RecruitingPhase 3
Ravulizumab for Neuromyelitis Optica Spectrum Disorder in Chinese Adults
This study tests a new medicine called ravulizumab (an infusion) to reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition affecting the optic nerve and spinal cord. The trial is specifically enrolling adults in China who have had recent disease activity.
BeijingAges 18–130 - NCT07543744RecruitingPhase 1
Comparing RPH-030 to Vectibix for metastatic colorectal cancer
This trial tests whether a new drug called RPH-030 works similarly to an existing drug called Vectibix in treating advanced colorectal cancer that has spread. Both drugs will be given alongside chemotherapy (FOLFIRI) as a first-line treatment.
ArkhangelskAges 18 years+ - NCT07536308RecruitingPhase 1
Nasal COVID-19 booster vaccine safety trial
This trial tests a new nasal spray COVID-19 booster vaccine. It aims to see if the vaccine is safe and produces a strong immune response when given through the nose and inhaled, in people who have already been vaccinated.
Decatur, GeorgiaAges 18–64 - NCT06734832RecruitingPhase 3
Vaccine trial for hand, foot, and mouth disease
This trial tests a new two-in-one vaccine to protect children against hand, foot, and mouth disease caused by two common viruses (EV71 and CA16). It is for healthy kids ages 6 months to 5 years and will check if the vaccine is safe and works well.
Hefei, AnhuiAges 6 months–5.9 years - NCT07520214Enrolling by invitationEarly Phase 1
Cancer vaccine to prevent glioblastoma recurrence
This early-stage study tests a personalized cancer vaccine designed to prevent glioblastoma (a serious brain tumor) from coming back after surgery and standard treatment. The vaccine aims to train your immune system to recognize and attack any remaining cancer cells.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07509047RecruitingPhase 2
Cholera vaccine safety study for adults and children
This trial tests a new cholera vaccine in healthy people ages 1 to 45. It aims to see if the vaccine is safe and creates a good immune response.
Nairobi, Kenyatta National Hospital ComplexAges 1–45 - NCT07505030Enrolling by invitationPhase 1
Safety study of LYNC-101 in healthy adults
This trial tests a new medicine called LYNC-101 in healthy volunteers to see if it is safe and how the body processes it. If you are a generally healthy adult between 18 and 60, you may be able to help researchers learn about this potential treatment.
Adelaide, South AustraliaAges 3 weeks–2 months - NCT07500506RecruitingPhase 3
Safety of a fifth dose of the Lyme disease vaccine
This study is for people who have already received four doses of the Lyme vaccine (VLA15) in a previous study. It tests whether a fifth dose is safe and helps the body build more protection against Lyme disease.
Bangor, MaineAges 7 years+ - NCT07500207Enrolling by invitationPhase 3
Rabies vaccine trial for people aged 10 to 60
This trial tests a new lyophilized rabies vaccine to see how well it works and how safe it is. It is for people who have not been vaccinated against rabies recently and have not been bitten or scratched by an animal that broke the skin in the past year.
Neijiang, SichuanAges 10–60 - NCT07485855RecruitingPhase 3
Flu vaccine study for blood cancer patients
This trial tests how well the flu vaccine works in people with blood cancers like lymphoma, leukemia, or multiple myeloma. It aims to find the best vaccination strategy to protect you during treatment.
SeoulAges 19 years+ - NCT07477587RecruitingPhase 1
Comparing two myeloma treatments for new patients
This trial tests a new drug combination (HLX15-SC) against an approved treatment (DARZALEX FASPRO) along with lenalidomide and dexamethasone for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant.
Springdale, ArkansasAges 18 years+ - NCT07476326RecruitingPhase 1
Comparing a new biosimilar to Opdivo for melanoma after surgery
This trial tests whether a new biosimilar drug (Bmab1700) works as well as the approved immunotherapy Opdivo (nivolumab) to prevent melanoma from coming back after surgery. You would receive either the biosimilar or Opdivo for about a year, and researchers will compare how your body handles the drug and its safety.
Bento GonçalvesAges 18 years+ - NCT07467707RecruitingPhase 3
Chikungunya vaccine trial for teens and adults
This trial tests an experimental chikungunya vaccine (made from a virus-like particle) to see if it prevents the disease. It is for healthy teens and adults who have not had chikungunya before.
Cebu City, CebuAges 12 years+ - NCT07425821RecruitingPhase 1
Marburg Virus Vaccine Safety Trial
This trial tests a new vaccine to protect against Marburg virus, a rare but serious infection. The vaccine uses a weakened virus to teach your body to fight the Marburg virus, and researchers are checking if it is safe and how well it works.
Washington D.C., District of ColumbiaAges 18–50 - NCT04975178RecruitingPhase 3
Test of a TB vaccine for newborns in sub-Saharan Africa
This Phase 3 study tests whether MTBVAC can safely protect newborn babies from tuberculosis and whether it helps the baby’s immune system learn to fight TB. If you enroll, the goal is to see safety and immune response in real newborn settings in sub-Saharan Africa.
Worcester, Western CapeAges 5 minutes–1 week - NCT06754605RecruitingPhase 1/Phase 2
Testing a new RSV vaccine for safety and immune response
This trial tests a new RSV vaccine in two phases. First, it will be given to healthy adults 18 and older to check safety. Then, it will be studied in adults 50 and older, including those with stable health conditions, to see if it helps protect against RSV, a common virus that can cause serious breathing problems in older people.
Langfang, HebeiAges 18–120 - NCT07400003RecruitingPhase 1/Phase 2
Shingles mRNA vaccine safety and immune response study
This trial tests a new mRNA vaccine to prevent shingles (herpes zoster). It checks if the vaccine is safe and helps your body build immunity. It's for adults aged 40 or older (phase 1) or 50+ (phase 2).
XinjiangAges 40 years+ - NCT07395739RecruitingPhase 1
Safety and immune response test of a new meningitis B vaccine
This trial tests a new vaccine called DX-104 to see if it is safe and helps the body fight meningitis B. Healthy adults aged 18-50 can join to help find a better way to prevent this infection.
Perth, Western AustraliaAges 18–50 - NCT07384104Enrolling by invitationPhase 1
Comparing a new bone drug (SAL023) to Evenity in healthy volunteers
This trial tests a new medicine called SAL023 to see how it compares to an approved drug (Evenity) in healthy people. It looks at how the body processes the drug, safety, and immune response. You must be healthy, within a certain age and weight range, and not have any bone or heart problems.
Hefei, AnhuiAges 18–45 - NCT07379580RecruitingPhase 2
Test of an mRNA vaccine for mpox in Africa
This trial tests a new mRNA vaccine to prevent mpox. It looks at how safe and effective the vaccine is in adults who have or haven't been exposed to mpox or similar viruses before.
KinshasaAges 18–64 - NCT07358156RecruitingPhase 1
Comparing a new dupilumab medicine to Dupixent in healthy adults
This trial tests a new version of Dupixent® (called CKD-706) to see how it compares to the approved medicine in healthy adults. It's a first step to make sure the new medicine works similarly and is safe.
Berlin, State of BerlinAges 18–55 - NCT07356050Recruiting
Measles vaccine study for children with sickle cell disease
This study checks if the measles vaccine works well in children with sickle cell disease. It aims to help protect children with this condition from measles.
Cincinnati, OhioAges 6 months–6 years - NCT07330440Enrolling by invitationPhase 1
MRNA vaccine study for preventing genital herpes
This study tests a new mRNA vaccine designed to protect against herpes simplex virus type 2 (HSV-2), the virus that causes genital herpes. It is for healthy adults who have not had a genital herpes outbreak in the last 6 months.
BeijingAges 18–55 - NCT07321808Recruiting
Shingles vaccine study for frail patients
This study tests how well the shingles vaccine works in people with weakened immune systems due to conditions like rheumatoid arthritis, cancer, or multiple sclerosis. It aims to see if the vaccine is safe and effective for these patients.
Pavia, PaviaAges Any age
Hear when a new Immunogenicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunogenicity?
- Yes. Clin2 currently lists 146 recruiting immunogenicity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunogenicity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunogenicity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.